Reuters logo
BRIEF-Ligand expects revenue related to Captisol material sales to be unchanged
January 18, 2017 / 10:59 PM / 8 months ago

BRIEF-Ligand expects revenue related to Captisol material sales to be unchanged

Jan 18 (Reuters) - Ligand Pharmaceuticals Inc :

* Ligand Pharmaceuticals - companies must adopt standard issued by FASB in may 2014 after january 1, 2017 and no later than january 1, 2018

* Ligand Pharmaceuticals Inc- company anticipates the standard will have a material impact on its consolidated financial statements - SEC filing

* Ligand Pharmaceuticals Inc - expects revenue related to Captisol material sales to remain unchanged

* Ligand Pharma-most significant impact from standards relates to accounting for revenues related to royalties, contingent "milestone" based payments Source text: (bit.ly/2iKzF6w) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below